Chijioke Okereke, MD
|Hometown: Boston, Massachusetts|
|Medical School: American University of Antigua College of Medicine|
|Residency: Medical College of Georgia|
|Research/Academic Interests: Translational research and clinical trials in Acute Myelocytic Leukemia and Multiple Myeloma; Cellular and Immuno-therapy; Gastrointestinal cancers|
|Bio: Anything that involves food, traveling and time spent with family. I also love movies (#1 Sci-Fi), running, hiking, museums, reading, music, documentaries, video games and watching sports. When traveling, I explore, learn and familiarize myself with a countries’ and/or area’s culture.|
- Okereke, C., Fox, A.D., Le, T., Abbagoni, S., Jillella, A.P., Bryan, L.J., Anwar, T., Mian, M.A. & Kota, V.. (2021, Nov). The Increased Use of Diagnostic Studies over Time in Acute Myelogenous Leukemia Patients. Blood, 138(Supplement 1), 4979.
- Fox, A.D., Okereke, C., Le, T., Jillella, A.P., Bryan, L.J., Anwar, T., Mian, M.A., Bradshaw, D., Kolhe, R., Savage, N.M., Ajebo, G., Padala, S., Abbagoni, S., & Kota, V.. (2021, Nov). Serum Albumin As a Prognostic Factor for Overall Survival at 6-Months in Acute Myeloid Leukemia (AML). Blood, 138(Supplement 1), 1226.
- Branham, Z. C., Okereke, C., Shoukier, M., Bradshaw, D., Kolhe, R., Jillella, A. P., & Kota, V. K. (2022). Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy. In Blood (Vol. 140, Issue Supplement 1, pp. 8929–8929). American Society of Hematology. doi:10.1182/blood-2022-164963